J. Otto

发表

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

Anatomical pulmonary resections for primary lung cancer in octogenarians within a dedicated care protocol.

J. Mouroux, N. Vénissac, M. Poudenx, 2019, Journal of thoracic disease.

Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer

J. Darcourt, R. Schiappa, S. Morbelli, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?

G. Poissonnet, P. Marcy, O. Dassonville, 2004, Cancer.

Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.

C. Marquette, P. Hofman, V. Esnault, 2013, Lung cancer.

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

J. Mazières, C. Mascaux, G. Zalcman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

O. Molinier, J. Pujol, M. Denis, 2020, Journal of clinical medicine.

Renal tolerance of cisplatin in patients more than 80 years old.

O. Dassonville, M. Gaspard, A. Thyss, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour response to paclitaxel in an adult with relapsed nephroblastoma.

A. Italiano, F. Peyrade, J. Michiels, 2005, The Lancet. Oncology.

Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer

J. Darcourt, R. Schiappa, S. Morbelli, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation.

D. Shahbazian, J. Benzaquen, P. Hofman, 2020, JCO precision oncology.

Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors

X. Pivot, G. Milano, J. Ferrero, 1997, Pharmacotherapy.

Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.

N. Magné, X. Pivot, G. Milano, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of Cisplatin‐Doxorubicin‐Cyclophosphamide in Adenocarcinoma of Unknown Primary Site: A Phase II Trial

N. Magné, X. Pivot, A. Thyss, 2001, American journal of clinical oncology.

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.

O. Dassonville, F. Demard, G. Milano, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of a circulating immunological signature predictive of response to immune checkpoint inhibitors in patients with advanced non‐small cell lung cancer

C. Marquette, P. Brest, J. Benzaquen, 2022, Clinical and translational medicine.

Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.

A. Falk, M. Poudenx, J. Barrière, 2012, Lung cancer.

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors

G. Milano, P. Brest, F. Peyrade, 2019, Investigational New Drugs.

Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C.

Gaëlle Pérot, A. Aurias, A. Italiano, 2006, Cancer genetics and cytogenetics.

An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia.

N. Magné, X. Pivot, G. Milano, 2000, European journal of cancer.

A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial

O. Molinier, J. Pujol, M. Denis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Deep Learning Facilitates Distinguishing Histologic Subtypes of Pulmonary Neuroendocrine Tumors on Digital Whole-Slide Images

N. Ayache, C. Marquette, J. Benzaquen, 2022, Cancers.

Skeletal Muscle Metastasis from Non-small Cell Lung Cancer

J. Mouroux, N. Vénissac, M. Poudenx, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

O. Molinier, M. Denis, D. Moro-Sibilot, 2021, Clinical Cancer Research.

Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.

C. Marquette, R. Schiappa, J. Benzaquen, 2020, Bulletin du cancer.

Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

P. Bondiau, A. Naghavi, D. Maneval, 2019, BMC Cancer.

NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?

C. Marquette, S. Leroy, P. Hofman, 2017, Expert review of anticancer therapy.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

D. Moro-Sibilot, B. Besse, R. Descourt, 2017, Oncotarget.

Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.

P. Bondiau, R. Schiappa, A. Naghavi, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature].

N. Magné, M. Namer, K. Bénézery, 2002, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Primary lung sarcomas: long survivors obtained with iterative complete surgery.

N. Magné, P. Marcy, X. Pivot, 2001, Lung cancer.

High-dose chemotherapy with autologous stem cell support in an adult with bone marrow relapse of medulloblastoma

N. Magné, P. Bondiau, A. Thyss, 2000, Bone Marrow Transplantation.

Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin.

X. Pivot, A. Thyss, M. Schneider, 1999, Hematology and Cell Therapy.

Multidisciplinary Management of Lung Cancer: How to Test Its Efficacy?

Francesco Leo, J. Mouroux, F. Leo, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acceptance of the 2009 A(H1N1) influenza vaccine among hospital workers in two French cancer centers.

F. Peyrade, E. Chamorey, M. Esteve, 2010, Vaccine.

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

O. Molinier, J. Pujol, P. Dumont, 2020, European journal of cancer.

Cisplatin-Docetaxel Induction plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial

P. Bondiau, J. Mouroux, E. Chamorey, 2012, Oncology.

Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: a prospective study of 100 episodes.

N. Magné, R. Largillier, E. Chamorey, 2004, Medical science monitor : international medical journal of experimental and clinical research.

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

J. Darcourt, R. Schiappa, J. Benzaquen, 2020, Journal for ImmunoTherapy of Cancer.

Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non–Small Cell Lung Cancer

J. Mouroux, N. Vénissac, M. Poudenx, 2017, The Thoracic and Cardiovascular Surgeon.

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System

C. Marquette, J. Benzaquen, P. Hofman, 2021, Frontiers in Pharmacology.

Recurrent desmoid tumour on a gortex patch.

P. Bondiau, P. Marcy, F. Peyrade, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

X. Pivot, G. Milano, P. Canal, 2000, European journal of cancer.

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

N. Girard, J. Mazières, P. Dubray-Longeras, 2022, European journal of cancer.

[Setting up a department of molecular pathology in oncology in a pathology laboratory (LPCE, CHU de Nice)].

C. Marquette, L. Castillo, J. Santini, 2013, Annales de pathologie.

Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer

C. Marquette, P. Bondiau, R. Schiappa, 2023, Radiation Oncology.

Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

P. Bondiau, A. Naghavi, D. Maneval, 2019, BMC Cancer.

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

C. Marquette, J. Sabourin, P. Hofman, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors.

A. Italiano, P. Marcy, D. Fontaine, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[Reappraisal of the role of endobronchial brachytherapy in the management of lung cancer: ten years' experience at the centre Antoine-Lacassagne].

N. Magné, S. Marcié, P. Marcy, 2003, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[Feasibility and efficacy of cyberknife radiotherapy for lung cancer: early results].

P. Bondiau, J. Thariat, J. Castelli, 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Amifostine Can Reduce Oral Mucositis after High-Dose Melphalan Conditioning in Patients with Multiple Myeloma: A Retrospective Study.

A. Italiano, F. Peyrade, E. Chamorey, 2004 .

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors

G. Milano, P. Brest, F. Peyrade, 2019, Investigational New Drugs.

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

P. Tomasini, F. Guisier, R. Gervais, 2023, Lung cancer.

Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

J. Mazières, J. Pujol, C. Mascaux, 2021 .